Skip to main content

Table 1 Baseline characteristics of eligible patients

From: Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer

  BBP group (%)
N = 37
Non-BBP group (%)
N = 25
P-value
Sex
 Male 19 (51.4) 8 (32.0) 0.192
 Female 18 (48.6) 17 (68.0)
Age (years)
 Median (range) 59 (34–82) 57 (27–74) 0.503
ECOG PS
 0 12 (32.4) 7 (28.0) 0.010
 1 21 (56.8) 7 (28.0)
 2≤ 3 (8.1) 10 (40.0)
 Unknown 1 (2.7) 1 (4.0)
RAS status
 KRAS/RAS wild type 11 (32.4) 19 (76.0) 0.001
 KRAS/RAS mutant 20 (54.0) 4 (16.0)
 Unknown 6 (16.2) 2 (8.0)
Primary location
 Right sidea 16 (43.2) 10 (40.0) 1.000
 Left sideb 21 (56.8) 15 (60.0)
Disease status
 Stage IV 24 (64.9) 21 (84.0) 0.147
 Recurrence 13 (35.1) 4 (16.0)
Number of metastatic organ sites
 1 13 (35.1) 5 (20.0) 0.259
 2≤ 24 (64.9) 20 (80.0)
Metastatic sites
 Liver 32 (86.5) 18 (72.0) 0.198
 Lung 14 (37.8) 9 (36.0) 1.000
 Lymph node 13 (35.1) 12 (48.0) 0.429
 Peritoneum 8 (21.6) 12 (48.0) 0.051
First-line chemotherapy
 Oxaliplatin-based regimen 31 (83.8) 24 (96.0) 0.225
 Irinotecan-based regimen 6 (16.2) 1 (4.0)
  1. Abbreviation: BBP Bevacizumab continuation beyond progression
  2. a: Appendix, caecum, ascending colon, hepatic flexure and transverse colon
  3. b: Splenic flexure, descending colon, sigmoid colon and rectum